In re Seroquel XR
Apr, 2025
In re Seroquel XR (Extended-Release Quetiapine Fumarate) Litigation (D. Del.)
This is a federal antitrust action brought on behalf of a class of direct purchasers seeking to recover overcharges for the delayed market entry of generic versions of Seroquel XR, which is prescribed to treat major depressive disorder, bipolar disorder, and schizophrenia. NastLaw represents a class of persons and entities that purchased brand or generic Seroquel XR directly from one of the named Defendants.